期刊
WEST INDIAN MEDICAL JOURNAL
卷 63, 期 6, 页码 650-654出版社
UNIV WEST INDIES FACULTY MEDICAL SCIENCES
DOI: 10.7727/wimj.2013.241
关键词
Antigenic targets; cancer therapy; clinical benefits; monoclonal antibodies
Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据